News & Updates

Neoadjuvant–adjuvant bests adjuvant-only pembrolizumab in advanced melanoma
Neoadjuvant–adjuvant bests adjuvant-only pembrolizumab in advanced melanoma
14 Mar 2023

For patients with stage III or IV melanoma, treatment with pembrolizumab both before and after surgical resection leads to longer event-free survival than treatment with pembrolizumab only after the procedure, according to the results of a phase II study.

Neoadjuvant–adjuvant bests adjuvant-only pembrolizumab in advanced melanoma
14 Mar 2023
Outpatient oritavancin reduces hospitalization in acute uncomplicated cellulitis
Outpatient oritavancin reduces hospitalization in acute uncomplicated cellulitis
13 Mar 2023

Outpatient oritavancin therapy for patients with acute uncomplicated cellulitis results in a decrease in 30-day hospital readmissions or admissions when compared with inpatient standard of care (SoC), a recent study has shown.

Outpatient oritavancin reduces hospitalization in acute uncomplicated cellulitis
13 Mar 2023
STELLAR trial offers hope for rare heart-lung disorder
STELLAR trial offers hope for rare heart-lung disorder
13 Mar 2023 byAudrey Abella

The phase III STELLAR trial lives up to its name, delivering stellar results and offering hope for patients with pulmonary arterial hypertension (PAH), a rare, progressive, life-threatening disorder affecting the heart and lungs, by adding sotatercept – a novel first-in-class activin signalling inhibitor – to background therapy.

STELLAR trial offers hope for rare heart-lung disorder
13 Mar 2023
Short-term risk of certain cancers similar in RA, PsA patients treated with JAK, TNF inhibitors
Short-term risk of certain cancers similar in RA, PsA patients treated with JAK, TNF inhibitors
12 Mar 2023

For patients with rheumatoid arthritis (RA) or psoriatic arthritis (PsA), initiation of Janus kinase (JAK) inhibitor treatment does not carry a higher short-term risk of cancer, with the exception of nonmelanoma skin cancer (NMSC), as compared with initiation of biological disease-modifying antirheumatic drugs (bDMARDs) including tumour necrosis factor (TNF) inhibitors, according to a study.

Short-term risk of certain cancers similar in RA, PsA patients treated with JAK, TNF inhibitors
12 Mar 2023
Augmentation therapy with aripiprazole gets a win for difficult-to-treat depression
Augmentation therapy with aripiprazole gets a win for difficult-to-treat depression
10 Mar 2023